BrainsWay Ltd. reported that its accelerated SWIFT Deep Transcranial Magnetic Stimulation protocol for major depressive disorder achieved response and remission rates comparable to the standard 20‑visit regimen while cutting the acute treatment phase to just six half‑days. The data, published in Brain Stimulation, show an 87.8% response rate and a 78.0% remission rate for SWIFT versus 86.5% and 76.5% for the standard protocol, with median time to remission of 21 days compared with 28 days for the conventional schedule.
The accelerated protocol reduces clinic visits by roughly 70%, lowering the acute treatment phase from 20 visits to 6 half‑days. This reduction translates into faster patient access, higher adherence, and lower operational costs for providers. The clinical equivalence in efficacy, coupled with a shorter treatment timeline, positions SWIFT as a patient‑centric alternative that could broaden BrainsWay’s reach in the U.S. market.
Payer coverage is expanding: Premera Blue Cross Blue Shield has adopted a policy covering the SWIFT protocol, and Evernorth Behavioral Health announced the elimination of prior authorization for TMS treatment effective March 6 2026. These developments remove key reimbursement barriers and are expected to accelerate adoption. Colleen A. Hanlon, Ph.D., Vice President of Medical Affairs, noted that “SWIFT demonstrates that we can substantially reduce treatment burden without compromising on outcomes, which fundamentally changes what access looks like for patients.”
Financially, BrainsWay has shown a strong trajectory. In Q1 2024 revenue rose 37% year‑over‑year, and the company reported positive net income and adjusted EBITDA for consecutive quarters. Full‑year 2024 revenue reached $41.0 million, a 29% increase over 2023, underscoring the company’s ability to scale its core product while maintaining profitability. The new protocol’s potential to increase patient throughput aligns with BrainsWay’s recurring‑revenue model and supports its growth strategy.
The accelerated protocol’s clinical success, coupled with expanding payer coverage and a solid financial foundation, signals a significant step forward for BrainsWay’s market penetration and long‑term revenue prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.